UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 19, 2005
MGI PHARMA, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Minnesota | | 0-10736 | | 41-1364647 |
(State or other jurisdiction of incorporation) | | (Commission file number) | | (I.R.S. Employer Identification No.) |
5775 West Old Shakopee Road, Suite 100, Bloomington, Minnesota 55437
(Address of principal executive offices)
Registrant’s telephone number, including area code: (952) 346-4700
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 2 – Financial Information
Item 2.02 Results of Operations and Financial Condition
The following information is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing:
On October 19, 2005, the Company issued a press release and held a conference call to report its results of operations and financial condition for the completed quarter ended September 30, 2005. The release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
Section 9– Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
| | |
| 99.1 | | Press Release dated October 19, 2005 of MGI PHARMA, INC. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| | | | |
| Date: October 19, 2005 | | MGI PHARMA, INC. |
| | |
| | | By: | | /s/ James C. Hawley
|
| | | | | James C. Hawley |
| | | | | Senior Vice President and Chief Financial Officer |
3
EXHIBIT INDEX
| | |
| 99.1 | | Press Release dated October 19, 2005 of MGI PHARMA, INC. |
4
